Imexpharm

Imexpharm FCF/Debt

The Free Cash Flow to Debt Ratio of Imexpharm (IMP.VN) as of Oct 27, 2026 is 12.83 %. In the previous year, Free Cash Flow to Debt Ratio was 138.75 % — a change of -90.76% (lower).

FCF/Debt

12.83 %

YoY

-90.76%

Last updated:

Free Cash Flow to Debt Ratio of Imexpharm is 2025 12.83 % . Free Cash Flow to Debt Ratio of Imexpharm was 2024 138.75 % . It decreases by -90.76% lower compared to the previous year.

The Imexpharm FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-171.73 VND
Jan 1, 2020
-12.63 VND
Jan 1, 2021
69.00 VND
Jan 1, 2022
294.01 VND
Jan 1, 2023
-209.55 VND
Jan 1, 2024
138.75 VND
Jan 1, 2025
12.83 VND
The Imexpharm FCF/Debt history
YEARFCF/DebtYoY
12.83 %-90.76%
138.75 %-166.21%
-209.55 %-171.27%
294.01 %+326.09%
69.00 %-646.50%
-12.63 %-92.65%
-171.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Free Cash Flow to Debt Ratio of Imexpharm is 12.83 % in 2025.

Free Cash Flow to Debt Ratio of Imexpharm changed from 138.75 % to 12.83 %, representing a -90.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Imexpharm since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Imexpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Imexpharm

All Key Metrics — Imexpharm